1. Home
  2. SLQT vs HUMA Comparison

SLQT vs HUMA Comparison

Compare SLQT & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SelectQuote Inc.

SLQT

SelectQuote Inc.

HOLD

Current Price

$1.35

Market Cap

281.6M

Sector

Finance

ML Signal

HOLD

Logo Humacyte Inc.

HUMA

Humacyte Inc.

HOLD

Current Price

$1.13

Market Cap

236.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLQT
HUMA
Founded
1999
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
281.6M
236.0M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
SLQT
HUMA
Price
$1.35
$1.13
Analyst Decision
Hold
Strong Buy
Analyst Count
2
8
Target Price
$3.88
$10.13
AVG Volume (30 Days)
878.2K
4.2M
Earning Date
02-09-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,563,142,000.00
$1,571,000.00
Revenue This Year
$13.00
N/A
Revenue Next Year
$7.65
$731.05
P/E Ratio
$10.82
N/A
Revenue Growth
13.16
N/A
52 Week Low
$1.33
$1.06
52 Week High
$6.86
$6.77

Technical Indicators

Market Signals
Indicator
SLQT
HUMA
Relative Strength Index (RSI) 38.17 37.60
Support Level $1.35 $1.06
Resistance Level $1.46 $1.17
Average True Range (ATR) 0.08 0.08
MACD 0.01 -0.01
Stochastic Oscillator 4.35 19.61

Price Performance

Historical Comparison
SLQT
HUMA

About SLQT SelectQuote Inc.

SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.

About HUMA Humacyte Inc.

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: